You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Gene Based Therapy for Congestive Heart Failure P2 SBIR

    SBC: Nanocor Therapeutics, Inc.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Congestive heart failure is a major cause of morbidity and mortality in the United States. While progress in conventional treatments is making steady and incremental gains to reduce heart failure mortality, there is a critical need to explore new therapeutic approaches. It is now apparent that gene therapy has broader potential in diseases such as congestive he ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Peptide-coated skin substitutes for the treatment of burn injuries and wounds

    SBC: AFFINERGY, LLC            Topic: 300

    DESCRIPTION provided by applicant Burn injuries and chronic wounds present a significant burden to patients and the US healthcare system Each year in the US there are burns that require medical treatment and burn patients that require hospitalization The mortality rate associated with severe burns can be as high as with of patient deaths arising from infection In add ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease

    SBC: Immunext, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Systemic lupus erythematosus SLE is a devastating autoimmune disease that most commonly affects women in their child bearing years SLE attacks multiple organ systems but renal and neurologic involvement are the usual harbingers of poor outcome Despite effective albeit toxic immunosuppressive therapy only of patients with these serious manifestations ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a Direct Cellular Energy Delivery System

    SBC: Vitatech, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Adenosine triphosphate (ATP) is the universal energy currency of the body and is made in large amounts by cells using substrate and oxygen. In the absence of oxygen, such as in disease states or surgical procedures that affect oxygen delivery, sufficient amounts of ATP cannot be produced and life ceases. We have developed a solution which can deliver large a ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  5. Novel therapeutics for fatty liver disease and type-II diabetes

    SBC: SOUTHEAST TECHINVENTURES INC            Topic: 200

    DESCRIPTION provided by applicant Western lifestyle and diet have spurred the growth of numerous obesity related disorders in the US including metabolic syndrome and type diabetes to epidemic proportions However less well known is the rising epidemic of non alcoholic fatty liver disease NAFLD NAFLD ranges from mild hepatosteatosis to severe fibrosis or cirrhosis and is initially charac ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Biological vector control reducing arboviruses, including Dengue and Chikungunya

    SBC: MosquitoMate, Inc            Topic: NIAID

    DESCRIPTION provided by applicant In the absence of effective approved drugs or vaccines vector control remains the only means of intervention for many against mosquito borne diseases This problem grows more complex with the recent establishment of multiple exotic mosquito species and mosquito borne pathogens Furthermore changing climate conditions are predicted to alter the traditional ra ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a drug discovery platform for human islets

    SBC: Zen-Bio, Inc.            Topic: 200

    DESCRIPTION provided by applicant Diabetes and diabetes related co morbidities are at epidemic proportions and an enormous burden to our healthcare system Although there has been significant progress in defining the causative factors and molecular mechanisms involved in both type and type diabetes it remains an overwhelming challenge to identify efficacious therapeutic modalities Novel a ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Therapeutic for the Negative Symptoms of Schizophrenia

    SBC: Darpharma, Inc.            Topic: N/A

    DESCRIPTION (PROVIDED BY APPLICANT): Schizophrenia affects roughly 1% of the world's population, with more than two million Americans afflicted in any given year, and an estimated 30-50 million people worldwide. Treatment with available antipsychotic medications often effectively attenuates the positive symptoms of schizophrenia without improvement in the negative symptoms or cognitive deficits. F ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  9. Multifunction High Throughput System for Neurophysiology of Behavior

    SBC: BIOGRAPHICS, INC.            Topic: 500

    DESCRIPTION provided by applicant The goal of this project is to create a system to conduct research with the assistance of a andapos High Throughput Multifunction System for Neurophysiology of Behaviorandapos This Phase II application to the Omnibus Solicitation is based on the Phase I for PA that was funded by NIAAA R AA The advanced system will provide capabilities for m ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Anti-biofilm agents for the treatment of pulmonary infection in cystic fibrosis p

    SBC: AGILE SCIENCES, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The leading cause of mortality in patients with cystic fibrosis CF is pulmonary failure from lung infections and the predominant organism isolated from these infections is the bacterium Pseudomonas aeruginosa Lung infections of CF patients persist over the lifetime of the patients and are impossible to eradicate due to the ability of bacteria to form biofi ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government